Ralph Zitnik

5.5k total citations · 4 hit papers
52 papers, 4.3k citations indexed

About

Ralph Zitnik is a scholar working on Immunology, Dermatology and Neurology. According to data from OpenAlex, Ralph Zitnik has authored 52 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 12 papers in Dermatology and 11 papers in Neurology. Recurrent topics in Ralph Zitnik's work include Psoriasis: Treatment and Pathogenesis (19 papers), Vagus Nerve Stimulation Research (11 papers) and Dermatology and Skin Diseases (11 papers). Ralph Zitnik is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (19 papers), Vagus Nerve Stimulation Research (11 papers) and Dermatology and Skin Diseases (11 papers). Ralph Zitnik collaborates with scholars based in United States, Netherlands and United Kingdom. Ralph Zitnik's co-authors include Andrea Wang, Alice B. Gottlieb, Craig L. Leonardi, Kim Papp, Bernard S. Goffe, Robert Matheson, Stephen K. Tyring, Angelika Jahreis, Yaakov A. Levine and Frieda A. Koopman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Ralph Zitnik

49 papers receiving 4.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etanercept as Monotherapy in Patients with Psoriasis

2003 935 citations Craig L. Leonardi, Bernard S. Goffe et al. profile →
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

2005 852 citations Alice B. Gottlieb, Craig L. Leonardi et al. profile →
Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis

2016 706 citations Frieda A. Koopman, Simeon Grazio et al. profile →
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

2005 557 citations Arline Nakanishi, Ralph Zitnik et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ralph Zitnik	2.2k	1.1k	830	680	599	52	4.3k
Raymond Hupperts	1.9k 0.8×	95 0.1×	305 0.4×	447 0.7×	635 1.1×	124	4.9k
Joost Smolders	1.9k 0.8×	90 0.1×	724 0.9×	263 0.4×	505 0.8×	103	4.1k
Roald Omdal	739 0.3×	178 0.2×	149 0.2×	1.3k 1.9×	463 0.8×	133	4.1k
Victoria Álvarez	768 0.3×	104 0.1×	382 0.5×	498 0.7×	1.8k 3.1×	199	5.4k
Yuhua Wang	2.7k 1.2×	1.1k 1.0×	60 0.1×	1.1k 1.6×	427 0.7×	79	4.0k
B. Seriolo	794 0.4×	410 0.4×	38 0.0×	1.2k 1.8×	408 0.7×	78	3.4k
Silvia Capellino	574 0.3×	120 0.1×	152 0.2×	619 0.9×	265 0.4×	51	2.1k
Richard J. Barohn	536 0.2×	299 0.3×	668 0.8×	1.5k 2.2×	2.4k 3.9×	191	10.0k
Paulo Louzada‐Júnior	911 0.4×	49 0.0×	118 0.1×	1.0k 1.5×	720 1.2×	152	3.1k
Chiara Briani	299 0.1×	536 0.5×	167 0.2×	509 0.7×	706 1.2×	208	5.5k

Countries citing papers authored by Ralph Zitnik

Since Specialization

Citations

This map shows the geographic impact of Ralph Zitnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Zitnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Zitnik more than expected).

Fields of papers citing papers by Ralph Zitnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Zitnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Zitnik. The network helps show where Ralph Zitnik may publish in the future.

Co-authorship network of co-authors of Ralph Zitnik

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph Zitnik. A scholar is included among the top collaborators of Ralph Zitnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph Zitnik. Ralph Zitnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Szefler, Stanley J., Jonathan Corren, Jonathan I. Silverberg, et al.. (2024). Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II). Immunotherapy. 16(20-22). 1211–1216. 3 indexed citations

Corren, Jonathan, Stanley J. Szefler, Ellen Sher, et al.. (2024). Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology In Practice. 12(5). 1215–1224.e3. 18 indexed citations

Clynes, Raphael, et al.. (2023). POS0119 XmAb564, A NOVEL POTENCY-REDUCED IL-2 FC FUSION PROTEIN SELECTIVELY EXPANDS REGULATORY T CELLS: RESULTS FROM A SINGLE ASCENDING DOSE STUDY IN HEALTHY ADULT VOLUNTEERS. 275.1–275.

Szefler, Stanley J., Jonathan Corren, Jonathan I. Silverberg, et al.. (2023). Lebrikizumab Decreases Inflammatory Biomarkers in Patients with Asthma: Data from Randomized Phase 3 Trials (LAVOLTA I and II). Journal of Allergy and Clinical Immunology. 151(2). AB195–AB195. 2 indexed citations

D’Haens, Geert, Michael Eberhardson, Silvio Danese, et al.. (2023). Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn’s Disease Patients: A Prospective Open-label Study. Journal of Crohn s and Colitis. 17(12). 1897–1909. 33 indexed citations

Grazio, Simeon, et al.. (2018). [VAGAL NERVE STIMULATION IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS – RESULTS THROUGH DAY 84 OBTAINED AT THE CROATIAN CENTER OF AN INTERNATIONAL PILOT STUDY].. PubMed. 63(2). 1–8. 1 indexed citations

Tang, Man, F. Samuel van Nierop, Frieda A. Koopman, et al.. (2017). Single vagus nerve stimulation reduces early postprandial C-peptide levels but not other hormones or postprandial metabolism. Clinical Rheumatology. 37(2). 505–514. 6 indexed citations

Zitnik, Ralph. (2011). Treatment of chronic inflammatory diseases with implantable medical devices. Annals of the Rheumatic Diseases. 70. i67–i70. 13 indexed citations

Zitnik, Ralph. (2011). Treatment of chronic inflammatory diseases with implantable medical devices*. Cleveland Clinic Journal of Medicine. 78(8 suppl 1). S30–S34. 15 indexed citations

10.

Hutmacher, Matthew M., et al.. (2007). Modeling the Exposure‐Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis. The Journal of Clinical Pharmacology. 47(2). 238–248. 9 indexed citations

11.

Nestorov, Ivan, Ralph Zitnik, Todd DeVries, et al.. (2006). Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. British Journal of Clinical Pharmacology. 62(4). 435–445. 40 indexed citations

12.

Gordon, Kenneth B., Neil J. Korman, Ellen Frankel, et al.. (2006). Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. Journal of the American Academy of Dermatology. 54(3). S101–S111. 84 indexed citations

13.

Gottlieb, Alice B., Craig L. Leonardi, Bernard S. Goffe, et al.. (2006). Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. Journal of the American Academy of Dermatology. 54(3). S92–S100. 57 indexed citations

14.

Lebwohl, Mark, et al.. (2005). No Evidence for Increased Risk of Cutaneous Squamous Cell Carcinoma in Patients With Rheumatoid Arthritis Receiving Etanercept for Up to 5 Years. Archives of Dermatology. 141(7). 861–4. 43 indexed citations

15.

Nestorov, Ivan, Ralph Zitnik, & Thomas M. Ludden. (2004). Population Pharmacokinetic Modeling of Subcutaneously Administered Etanercept in Patients with Psoriasis. Journal of Pharmacokinetics and Pharmacodynamics. 31(6). 463–490. 17 indexed citations

16.

Wright, Clifford D., John A. Kennedy, Ralph Zitnik, & Mohammed A. Kashem. (1999). Inhibition of Murine Neutrophil Serine Proteinases by Human and Murine Secretory Leukocyte Protease Inhibitor. Biochemical and Biophysical Research Communications. 254(3). 614–617. 30 indexed citations

17.

Zitnik, Ralph, Jue Zhang, Mohammed A. Kashem, et al.. (1997). The Cloning and Characterization of a Murine Secretory Leukocyte Protease Inhibitor cDNA. Biochemical and Biophysical Research Communications. 232(3). 687–697. 48 indexed citations

18.

Zitnik, Ralph, et al.. (1994). Glucocorticoid Inhibition of Interleukin-1-Induced Interleukin-6 Production by Human Lung Fibroblasts: Evidence for Transcriptional and Post-Transcriptional Regulatory Mechanisms. American Journal of Respiratory Cell and Molecular Biology. 10(6). 643–650. 50 indexed citations

19.

Zitnik, Ralph, et al.. (1992). Effects of In Vitro Amiodarone Exposureon Alveolar Macrophage Inflammatory Mediator Production. The American Journal of the Medical Sciences. 304(6). 352–356. 5 indexed citations

20.

Cooper, John A., Ralph Zitnik, & Richard A. Matthay. (1988). Mechanisms of Drug-Induced Pulmonary Disease. Annual Review of Medicine. 39(1). 395–404. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact